Eli Lilly Coronavirus Antibody Bamlanivimab was revoked by FDA

Eli Lilly Coronavirus Antibody Bamlanivimab was revoked by FDA.   Burst! FDA revokes emergency use authorization of coronavirus antibody: Bamlanivimab developed by Eli Lilly.

The U.S. Food and Drug Administration (FDA) revoked the emergency use authorization (EUA) of Eli Lilly’s new coronavirus antibody drug Bamlanivimab.

The FDA announced the above decision on Friday. It issued a statement saying that the use of bamlanivimab alone to treat patients infected with new coronavirus pneumonia caused “an increasing risk of treatment failure.” Therefore, as a single treatment drug, the risk of using this drug is already higher than the possible curative effect, and there is no need to give EUA.

On October 28, 2020, Eli Lilly announced an agreement with the US government to supply 300,000 bottles of research antibody drugs for the treatment of COVID-19 at a price of US$375 million.

The agreement stipulates that if Eli Lilly obtains emergency use authorization from the U.S. Food and Drug Administration (FDA), the drug will be delivered within two months. The company said that according to other regulations, the US government can purchase up to 650,000 additional bottles before June 30, 2021.

It is worth noting that before the FDA announced on Friday that the emergency use authorization of Eli Lilly’s COVID-19 antibody drug was revoked, Eli Lilly had already admitted that due to some mutant viruses circulating in the United States, the effect of treatment with bamlanivimab alone has declined, and Eli Lilly will Focus on promoting the cocktail therapy of bamlanivimab and the company’s second antibody drug etesevimab.

Although the emergency authorization of the COVID-19 antibody drug bamlanivimab has been revoked, the FDA emphasized that the REGEN-COV antibody cocktail therapy, Eli Lilly bamlanivimab and etesevimab cocktail therapy are still available.

(source:internet, reference only)

Disclaimer of medicaltrend.org